Inventiva S.A. American Depository Shares (IVA)
Nasdaq: IVA · Pharmaceutical Preparations · Daix, FR · filing with the SEC since 2020
Who owns Inventiva S.A. American Depository Shares
As filed with the SECHolders of 5% or more
5
Invus Public Equities, L.P. holds 10.6% of Ordinary shares, nominal value Euro 0.01 per share, as its SCHEDULE 13G/A filed Jul 31, 2025 says.
Directors and officers
0
report now, of 0 people on the record since . Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Invus Public Equities, L.P.
SCHEDULE 13G/A · filed Jul 31, 2025 · Ordinary shares, nominal value Euro 0.01 per share · 7.8% in Mar 31, 2025
Sofinnova Partners SAS, a French corporation
SCHEDULE 13G/A · filed Feb 17, 2026 · Ordinary Shares, nominal value EUR0.01 per share · 7.2% in Feb 14, 2025
Srinivas Akkaraju
SCHEDULE 13D/A · filed Nov 19, 2025 · Ordinary shares, nominal value (euro) 0.01 per share · 5.9% in Oct 21, 2025
Andera Partners
SCHEDULE 13G/A · filed Oct 27, 2026 · Ordinary Shares, nominal value Euro 0.01 per share · 7.7% in Feb 17, 2026
Yiheng Capital Partners, L.P.
SCHEDULE 13G/A · filed Nov 13, 2025 · Ordinary shares, par value $0.01 per share · 8.31% in Nov 13, 2024
Bvf Partners L P/il
SCHEDULE 13D/A · filed Nov 19, 2025 · Ordinary Shares, nominal value (euro)0.01 per share · reported falling below 5%, from 6.1% in May 9, 2025
Perceptive Advisors LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Ordinary shares, nominal value euro 0.01 per share · reported falling below 5%, from 5.8% in Mar 26, 2025
New Enterprise Associates 17, L.P.
SCHEDULE 13D/A · filed Apr 1, 2026 · Ordinary Shares, (euro)0.01 par value per share · reported falling below 5%, from 6% in May 7, 2025
Eventide Asset Management, LLC
SCHEDULE 13G/A · filed Feb 13, 2026 · Ordinary Shares, nominal value Euro 0.01 per share · reported falling below 5%, from 6.7% in May 15, 2025
Pierre Broqua
SCHEDULE 13G/A · filed Feb 14, 2025 · Ordinary Shares, EUR0.01 par value per share · reported falling below 5%
Deep Track Capital, LP
SCHEDULE 13G/A · filed May 15, 2026 · Ordinary shares, nominal value 0.01 EUR per share · reported falling below 5%, from 6.07% in Jan 30, 2026
Great Point Partners, LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Ordinary shares, nominal value 0.01 Euro per share · reported falling below 5%, from 6.06% in Nov 14, 2025
What IVA reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Inventiva Inc
An entity · legal entity · owns, named in the 20-F filed Apr 8, 2026
Hepalys Pharma, Inc
An entity · co registrant · owns, named in the 20-F filed Apr 8, 2026
Hepalys Pharma, Inc
An investee · associate, legal entity · invested in, named in the 20-F filed Apr 8, 2026
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
No open-market trade is on the record for these years.
Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.